To investigate this phenomenon further and to gain insights into the role of the glymphatic system in disease progression, we conducted additional animal experiments in which we initiated drug treatment at either 2-weeks (early/mild stages of tauopathy) or 4-weeks (moderate stages of tauopathy) after tau inoculation [1] (Fig. 5A). This evidence concerns the gene MAPT and tauopathy.